Renal Anemia-Pipeline Review, H2 2015

Renal Anemia-Pipeline Review, H2 2015

  • Products Id :- GMDHC7230IDB
  • |
  • Pages: 124
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Renal Anemia-Pipeline Review, H2 2015


Global Markets Direct's, 'Renal Anemia-Pipeline Review, H2 2015', provides an overview of the Renal Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Renal Anemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Renal Anemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Renal Anemia Overview 10

Therapeutics Development 11

Pipeline Products for Renal Anemia-Overview 11

Renal Anemia-Therapeutics under Development by Companies 12

Renal Anemia-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Renal Anemia-Products under Development by Companies 18

Renal Anemia-Companies Involved in Therapeutics Development 21

Acceleron Pharma, Inc. 22

Akebia Therapeutics, Inc. 23

Amgen Inc. 24

Aprogen, Inc. 25

Bayer AG 26


CCM Duopharma Biotech Bhd. 28

Chong Kun Dang Pharmaceutical Corp. 29

Daiichi Sankyo Company, Limited 30

Dong-A Socio Group 31

Dr. Reddy's Laboratories Limited 32

Eli Lilly and Company 33

FibroGen, Inc. 34

GlaxoSmithKline Plc 35

Intas Pharmaceuticals Ltd. 36

Japan Tobacco Inc. 37

JCR Pharmaceuticals Co., Ltd. 38

Jiangsu Hansoh Pharmaceutical Co., Ltd. 39

Medgenics Inc. 40

Myungmoon pharmaceutical Co., Ltd. 41

Panacea Biotec Limited 42

Pfizer Inc. 43

ProMetic Life Sciences Inc. 44

Sandoz International GmbH 45

Zydus Cadila Healthcare Limited 46

Renal Anemia-Therapeutics Assessment 47

Assessment by Monotherapy Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

Biologic for Renal Anemia-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

daprodustat-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

darbepoetin alfa-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

darbepoetin alfa-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

darbepoetin alfa-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

darbepoetin alfa-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

darbepoetin alfa-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

darbepoetin alfa-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

darbepoetin alfa-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

darbepoetin alfa (recombinant)-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

DS-1093-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

EPO-018B-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

epoetin-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

epoetin alfa-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

epoetin alfa (recombinant)-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

FG-2216-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

JTZ-951-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

MDGN-201-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

MMP-0101-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

molidustat-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

PBI-1402-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

PEG-EPO-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Peg-EPO-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

PEG-EPO-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

PRS-080-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Recombinant Protein for Renal Anemia-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

roxadustat-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Small Molecule to Inhibit HIF-PH for Renal Anemia-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

sotatercept-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

SSS-06-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

vadadustat-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Renal Anemia-Recent Pipeline Updates 99

Renal Anemia-Dormant Projects 114

Renal Anemia-Discontinued Products 115

Renal Anemia-Product Development Milestones 116

Featured News & Press Releases 116

Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia 116

Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis 116

May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress 117

Mar 27, 2015: Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 117

Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN 118

Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat 119

Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease 120

Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201 120

Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan 121

Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease 121

Appendix 123

Methodology 123

Coverage 123

Secondary Research 123

Primary Research 123

Expert Panel Validation 123

Contact Us 123

Disclaimer 124

List of Tables

Number of Products under Development for Renal Anemia, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd...1) 19

Products under Development by Companies, H2 2015 (Contd...2) 20

Renal Anemia-Pipeline by 3SBio Inc., H2 2015 21

Renal Anemia-Pipeline by Acceleron Pharma, Inc., H2 2015 22

Renal Anemia-Pipeline by Akebia Therapeutics, Inc., H2 2015 23

Renal Anemia-Pipeline by Amgen Inc., H2 2015 24

Renal Anemia-Pipeline by Aprogen, Inc., H2 2015 25

Renal Anemia-Pipeline by Bayer AG, H2 2015 26

Renal Anemia-Pipeline by BIOCAD, H2 2015 27

Renal Anemia-Pipeline by CCM Duopharma Biotech Bhd., H2 2015 28

Renal Anemia-Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 29

Renal Anemia-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 30

Renal Anemia-Pipeline by Dong-A Socio Group, H2 2015 31

Renal Anemia-Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 32

Renal Anemia-Pipeline by Eli Lilly and Company, H2 2015 33

Renal Anemia-Pipeline by FibroGen, Inc., H2 2015 34

Renal Anemia-Pipeline by GlaxoSmithKline Plc, H2 2015 35

Renal Anemia-Pipeline by Intas Pharmaceuticals Ltd., H2 2015 36

Renal Anemia-Pipeline by Japan Tobacco Inc., H2 2015 37

Renal Anemia-Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015 38

Renal Anemia-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 39

Renal Anemia-Pipeline by Medgenics Inc., H2 2015 40

Renal Anemia-Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2015 41

Renal Anemia-Pipeline by Panacea Biotec Limited, H2 2015 42

Renal Anemia-Pipeline by Pfizer Inc., H2 2015 43

Renal Anemia-Pipeline by ProMetic Life Sciences Inc., H2 2015 44

Renal Anemia-Pipeline by Sandoz International GmbH, H2 2015 45

Renal Anemia-Pipeline by Zydus Cadila Healthcare Limited, H2 2015 46

Assessment by Monotherapy Products, H2 2015 47

Number of Products by Stage and Target, H2 2015 49

Number of Products by Stage and Mechanism of Action, H2 2015 51

Number of Products by Stage and Route of Administration, H2 2015 53

Number of Products by Stage and Molecule Type, H2 2015 55

Renal Anemia Therapeutics-Recent Pipeline Updates, H2 2015 99

Renal Anemia-Dormant Projects, H2 2015 114

Renal Anemia-Discontinued Products, H2 2015 115

List of Figures

Number of Products under Development for Renal Anemia, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 47

Number of Products by Top 10 Targets, H2 2015 48

Number of Products by Stage and Top 10 Targets, H2 2015 48

Number of Products by Mechanism of Actions, H2 2015 50

Number of Products by Stage and Mechanism of Actions, H2 2015 50

Number of Products by Routes of Administration, H2 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 52

Number of Products by Molecule Types, H2 2015 54

Number of Products by Stage and Molecule Types, H2 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Acceleron Pharma, Inc.

Akebia Therapeutics, Inc.

Amgen Inc.

Aprogen, Inc.

Bayer AG


CCM Duopharma Biotech Bhd.

Chong Kun Dang Pharmaceutical Corp.

Daiichi Sankyo Company, Limited

Dong-A Socio Group

Dr. Reddy's Laboratories Limited

Eli Lilly and Company

FibroGen, Inc.

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd.

Japan Tobacco Inc.

JCR Pharmaceuticals Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Medgenics Inc.

Myungmoon pharmaceutical Co., Ltd.

Panacea Biotec Limited

Pfizer Inc.

ProMetic Life Sciences Inc.

Sandoz International GmbH

Zydus Cadila Healthcare Limited

Renal Anemia Therapeutic Products under Development, Key Players in Renal Anemia Therapeutics, Renal Anemia Pipeline Overview, Renal Anemia Pipeline, Renal Anemia Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]